Robert F Kennedy Jr. Advises FDA to Approve Six Popular Peptides for Compounding Pharmacies
An advisory panel within the Food and Drug Administration recently recommended that six of the seven peptides under consideration be made legally available for compounding pharmacies. This move would allow these compounds to be sold as customized medications before the agency has fully proven their safety or effectiveness. The committee, which includes members with financial ties to the peptide industry, favored a reclassification method that leverages less-regulated compounding pharmacies to bypass stricter federal oversight. Robert F Kennedy Jr. has been a vocal advocate for these treatments, particularly the "Wolverine stack" of BPC-157 and TB-500. While the administration announced the committee's recommendation, the final decision rests with the FDA. If approved, the move will open a multi-billion dollar market for telehealth companies and compounding pharmacies. However, some medical experts expressed concern that the change may prioritize market demand over solid science, potentially disrupting the long-standing societal pact that drugs are studied thoroughly before being marketed to the public.